Profile data is unavailable for this security.
About the company
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.
- Revenue in CAD (TTM)11.96bn
- Net income in CAD-808.73m
- Incorporated2013
- Employees20.27k
- LocationBausch Health Companies Inc2150 Saint-Elzear Blvd WLAVAL H7L 4A8CanadaCAN
- Phone+1 (514) 744-6792
- Fax+1 (514) 744-6792
- Websitehttps://www.bauschhealth.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arcellx Inc | 110.32m | -70.69m | 2.90bn | 130.00 | -- | 5.86 | -- | 26.30 | -1.49 | -1.49 | 2.30 | 9.28 | 0.1937 | -- | -- | 848,607.70 | -12.41 | -38.82 | -14.67 | -45.41 | -- | -- | -64.08 | -339.38 | -- | -- | 0.0749 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
| Apogee Therapeutics Inc | 0.00 | -83.99m | 2.91bn | 91.00 | -- | 6.33 | -- | -- | -1.74 | -1.74 | 0.00 | 7.86 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
| Ideaya Biosciences Inc | 23.38m | -112.96m | 2.91bn | 124.00 | -- | 4.09 | -- | 124.42 | -1.96 | -1.96 | 0.4068 | 9.55 | 0.0451 | -- | 204.23 | 188,580.60 | -21.78 | -19.17 | -23.09 | -21.05 | -- | -- | -483.07 | -244.55 | -- | -- | 0.00 | -- | -54.08 | -- | -92.59 | -- | 6.75 | -- |
| Azenta Inc | 641.02m | -17.37m | 2.93bn | 3.50k | -- | 1.20 | 41.92 | 4.57 | -0.2978 | -0.315 | 10.31 | 43.86 | 0.2096 | 2.86 | 3.40 | 183,149.40 | -0.568 | -0.5934 | -0.6169 | -0.6725 | 39.12 | 43.08 | -2.71 | -2.17 | 5.33 | -- | 0.00 | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
| Arrowhead Pharmaceuticals Inc | 181.74m | -296.81m | 2.95bn | 525.00 | -- | 15.94 | -- | 16.21 | -2.77 | -2.77 | 1.69 | 1.49 | 0.2395 | -- | -- | 346,171.40 | -39.91 | -20.02 | -46.61 | -24.65 | -- | -- | -166.63 | -61.79 | -- | -55.19 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
| Xenon Pharmaceuticals Inc | 0.00 | -182.39m | 3.10bn | 251.00 | -- | 3.34 | -- | -- | -2.73 | -2.73 | 0.00 | 12.31 | 0.00 | -- | -- | 0.00 | -21.22 | -20.71 | -21.86 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
| Bausch Health Companies Inc | 8.76bn | -592.00m | 3.12bn | 20.27k | -- | -- | 4.78 | 0.3564 | -1.62 | -1.62 | 23.96 | -2.80 | 0.3302 | 1.94 | 4.62 | 432,017.80 | -2.30 | -2.74 | -2.85 | -3.31 | 70.78 | 71.59 | -6.98 | -9.78 | 0.9419 | 1.18 | 1.00 | -- | 7.79 | 0.884 | -163.11 | -- | 2.97 | -- |
| Amicus Therapeutics, Inc. | 399.36m | -151.58m | 3.16bn | 517.00 | -- | 19.63 | -- | 7.92 | -0.5148 | -0.5148 | 1.35 | 0.5456 | 0.5318 | 0.8939 | 5.19 | 772,448.80 | -20.18 | -30.65 | -25.36 | -36.55 | 90.65 | 88.94 | -37.96 | -86.10 | 2.52 | -1.76 | 0.7077 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
| SpringWorks Therapeutics Inc | 5.45m | -325.10m | 3.26bn | 305.00 | -- | 5.16 | -- | 598.24 | -5.14 | -5.14 | 0.0862 | 8.52 | 0.008 | -- | -- | 17,859.02 | -47.95 | -36.97 | -53.00 | -39.49 | 92.25 | -- | -5,968.50 | -2,176.46 | 6.37 | -- | 0.00 | -- | -- | -- | -17.19 | -- | 90.68 | -- |
| 10X Genomics Inc | 618.73m | -255.10m | 3.29bn | 1.26k | -- | 4.43 | -- | 5.31 | -2.18 | -2.18 | 5.28 | 6.22 | 0.6206 | 2.70 | 5.65 | 491,443.20 | -25.59 | -25.52 | -29.39 | -29.05 | 66.15 | 75.88 | -41.23 | -48.53 | 4.11 | -- | 0.00 | -- | 19.81 | 33.43 | -53.67 | -- | 49.15 | -- |
| Fortrea Holdings Inc | 3.11bn | -3.40m | 3.30bn | 18.00k | -- | 1.89 | 35.50 | 1.06 | -0.0379 | -0.0379 | 35.03 | 19.58 | -- | -- | -- | 172,722.20 | -- | -- | -- | -- | 16.74 | -- | -0.1094 | -- | -- | 1.27 | 0.478 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
| Iovance Biotherapeutics Inc | 1.19m | -444.04m | 3.31bn | 557.00 | -- | 5.20 | -- | 2,786.02 | -1.89 | -1.89 | 0.0051 | 2.28 | 0.0017 | -- | -- | 2,134.65 | -61.49 | -51.47 | -71.47 | -57.56 | -804.54 | -- | -37,345.42 | -137,873.80 | 2.70 | -- | 0.0017 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
| Simply Good Foods Co | 1.27bn | 140.76m | 3.38bn | 271.00 | 24.27 | 2.05 | 20.88 | 2.67 | 1.39 | 1.39 | 12.53 | 16.48 | 0.5977 | 6.91 | 8.56 | 4,671,908.00 | 6.65 | 3.66 | 6.95 | 3.83 | 37.26 | 38.90 | 11.12 | 6.80 | 3.09 | 9.26 | 0.1261 | 0.00 | 6.33 | 23.56 | 23.03 | 13.65 | 47.09 | -- |
| Crinetics Pharmaceuticals Inc | 4.01m | -214.53m | 3.45bn | 290.00 | -- | 5.59 | -- | 858.72 | -3.70 | -3.70 | 0.0691 | 7.91 | 0.0081 | -- | 0.7048 | 13,837.93 | -42.39 | -42.53 | -45.71 | -45.36 | -- | -- | -5,216.32 | -5,446.39 | -- | -- | 0.00 | -- | -15.28 | 10.57 | -30.88 | -- | 34.65 | -- |
Data as of Apr 24 2024. Currency figures normalised to Bausch Health Companies Inc's reporting currency: US Dollar USD
48.79%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Icahn Associates Holding LLCas of 05 Feb 2024 | 34.72m | 9.50% |
| GoldenTree Asset Management LPas of 31 Dec 2023 | 27.64m | 7.57% |
| Paulson & Co., Inc.as of 31 Dec 2023 | 26.44m | 7.24% |
| Franklin Advisers, Inc.as of 31 Dec 2023 | 15.78m | 4.32% |
| National Bank Financial, Inc.as of 31 Dec 2023 | 15.63m | 4.28% |
| Nomura Securities Co., Ltd. (Private Banking)as of 31 Dec 2023 | 13.30m | 3.64% |
| Healthcare of Ontario Pension Planas of 31 Dec 2023 | 13.00m | 3.56% |
| RBC Global Asset Management, Inc.as of 31 Dec 2023 | 11.62m | 3.18% |
| Hudson Bay Capital Management LPas of 31 Dec 2023 | 11.50m | 3.15% |
| Laurion Capital Management LPas of 31 Dec 2023 | 8.64m | 2.36% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
